How do drugs cross the blood brain barrier?

The blood brain barrier is a multicellular interface that tightly regulates movement between the bloodstream and neural tissue. Richard Daneman at University of California San Diego has characterized how brain capillary endothelial cells form continuous tight junctions that limit paracellular flow, while pericytes and astrocyte endfeet provide structural support and signaling that maintain barrier properties. This physical and biochemical specialization explains why most circulating compounds cannot readily enter the brain.<br><br>Passive diffusion and carrier-mediated transport<br>Small, lipophilic molecules cross the barrier more readily by dissolving in endothelial cell membranes and diffusing into brain tissue. William M. Pardridge at University of California Los Angeles has long emphasized that lipid solubility and low plasma protein binding increase passive penetration. Polar nutrients and many drugs that cannot diffuse are carried by specific transport proteins. Pardridge and others describe glucose transport via GLUT1 and large neutral amino acid transport via LAT1 as examples of carrier systems that sustain neural metabolism and can be exploited for drug delivery. Efflux pumps located on the luminal membrane, notably P-glycoprotein encoded by the ABCB1 gene and breast cancer resistance protein encoded by ABCG2, actively expel a broad range of drugs back into blood, limiting central nervous system exposure and contributing to treatment failure for some conditions.<br><br>Receptor-mediated and adsorptive transcytosis<br>Large biologic drugs and nanoparticles that cannot use carrier proteins may cross by receptor-mediated transcytosis or adsorptive-mediated pathways. William M. Pardridge at University of California Los Angeles and other researchers have developed strategies that attach therapeutic molecules to ligands for the transferrin receptor or insulin receptor, allowing vesicular transport across endothelial cells. Adsorptive-mediated uptake uses electrostatic interactions with the endothelial surface to promote vesicle formation. Emerging methods also harness transient opening of the barrier. Kullervo Hynynen at Sunnybrook Research Institute University of Toronto has led studies using focused ultrasound combined with microbubbles to create localized, reversible increases in permeability, enabling delivery of antibodies or chemotherapeutics to target regions.<br><br>Pathological disruption and societal consequences<br>Inflammation, hypertension, aging, and infection can disrupt barrier integrity, producing increased permeability that alters drug penetration and can precipitate neuroinflammation and neuronal injury. William A. Banks at University of Washington has described how cytokine signaling and systemic inflammation change transport dynamics and may worsen central nervous system disease. These biological changes have cultural and territorial implications: regions with higher burdens of infectious central nervous system disease or limited access to advanced delivery technologies face different clinical challenges. For example, treatments that rely on specialized infusion or image-guided focused ultrasound may be impractical where infrastructure and trained personnel are scarce, shaping priorities for oral or intrathecal therapies in those settings.<br><br>Understanding the mechanisms by which drugs cross the blood brain barrier informs both drug design and public health strategy. Combining knowledge of passive diffusion, transporter specificity, receptor-mediated routes, and disease-related barrier changes allows clinicians and researchers to balance efficacy and safety while considering local healthcare capabilities and environmental influences on barrier function.